Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial
The MARVEL Clinical Program is designed to assess functional capacity and
quality of life in patients with advanced heart failure after receiving
injection of adult muscle stem cell therapy in their damaged heart muscle
* The MARVEL Phase II/III clinical trials are set to become a global benchmark
study in CHF leading
* The 6 minute walk distance (6MWD, an established parameter of efficacy
utilized in heart failure studies), one of the primary end points of MARVEL Part
1, increased on average by more than 91 meters in cell-treated patients, whereas
in the placebo-treated group a decrease of nearly 4 meters was seen
* No significant stem cell related safety concerns
Continues...
http://www.reuters.com/article/pressRelease/idUS185942+16-Sep-2009+BW20090916
The MARVEL Clinical Program is designed to assess functional capacity and
quality of life in patients with advanced heart failure after receiving
injection of adult muscle stem cell therapy in their damaged heart muscle
* The MARVEL Phase II/III clinical trials are set to become a global benchmark
study in CHF leading
* The 6 minute walk distance (6MWD, an established parameter of efficacy
utilized in heart failure studies), one of the primary end points of MARVEL Part
1, increased on average by more than 91 meters in cell-treated patients, whereas
in the placebo-treated group a decrease of nearly 4 meters was seen
* No significant stem cell related safety concerns
Continues...
http://www.reuters.com/article/pressRelease/idUS185942+16-Sep-2009+BW20090916